Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver FibrosisGlobeNewsWire • 01/06/23
Traders who bet against stocks made a killing in 2022, as short sellers netted $300 billionCNBC • 01/06/23
Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom ProgramGlobeNewsWire • 12/21/22
Madrigal Pharmaceuticals Is Still Undervalued After Resmetirom's Phase 3 SuccessSeeking Alpha • 12/21/22
Madrigal Pharmaceuticals shares soar on positive trial results for its NASH and liver fibrosis drug resmetiromProactive Investors • 12/19/22
Madrigal Pharma Stock Triples After Knocking NASH Study Out Of The ParkInvestors Business Daily • 12/19/22
Madrigal's stock rallies about 200% after sharing positive data about its NASH treatment candidateMarket Watch • 12/19/22
Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NASH Study of Resmetirom on Monday, December 19thGlobeNewsWire • 12/18/22